NCT05659602

A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients

A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in Participants Diagnosed With Asymptomatic or Mild COVID-19

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 111 (actual)
• Sponsor: Beijing Ditan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the preliminary efficacy and safety of HH-120 nasal spray in the treatment of asymptomatic or mild COVID-19.

Detailed description

During this study, participants will receive HH-120 nasal spray treatment for 6 consecutive days, the efficacy and safety of HH-120 will be assessed throughout the study period based on viral clearance, clinical recovery, illness severity and adverse events.

Conditions

• Coronavirus Disease 2019(COVID-19)

Interventions

Type	Name	Description
BIOLOGICAL	HH-120 Nasal Spray	HH-120 Nasal Spray 8-10 times per day for 6 consecutive days

Timeline

• Start date: 2022-07-09
• Primary completion: 2023-01-03
• Completion: 2023-01-03
• First posted: 2022-12-21
• Last updated: 2024-10-10

Locations

1 site across 1 country: China